EGGXYT LTD

Their core work

EGGXYT LTD is an Israeli biotech SME that develops in-ovo sex determination technology for the commercial egg production industry. Their core product enables hatcheries to identify the sex of a chicken embryo on the very first day of incubation — before the egg enters the incubator — allowing male eggs to be diverted before any chick develops. This directly addresses one of the egg industry's most costly and controversial practices: the culling of approximately 7 billion male chicks per year worldwide. They progressed from a validated feasibility concept to a commercially deployable system within a 5-year H2020 arc, positioning themselves as a deep-tech solution provider at the intersection of poultry science, optical detection, and animal welfare compliance.

What they specialise in

How they've shifted over time

EGGXYT's H2020 trajectory is unusually linear and focused: they entered the program in 2017 with a single, well-defined technology thesis and used the SME instrument exactly as intended — first to validate feasibility (€50K, 6 months), then to develop and commercialize the full system (€2.33M, 3 years). There is no visible pivot or scope expansion between their two projects; the technology domain, application, and even the project name stayed the same. This consistency signals a company that is not exploring multiple ideas but executing a single high-conviction technology roadmap toward market readiness in the egg production sector.

EGGXYT has completed its EU-funded R&D phase and is most likely in or approaching commercial go-to-market; a collaboration inquiry today should be framed around licensing, pilot deployments, or integration partnerships rather than joint research.

How they like to work

EGGXYT has exclusively used the SME instrument, which is a solo-beneficiary funding scheme — meaning they have led both of their EU projects without any consortium partners. This is not unusual for deep-tech product startups using SME grants to fund proprietary technology development, but it does mean they have no documented experience as a multi-partner consortium member or sub-contractor within larger EU projects. Any future collaboration would likely need to be structured around a clear IP and licensing boundary, as their technology is a product, not a shared research platform.

EGGXYT has zero recorded consortium partners across their two H2020 projects, reflecting the solo nature of SME instrument grants. Their network footprint within the EU research system is minimal on paper, though their commercial network in the poultry industry may be substantial and undocumented in CORDIS.

What sets them apart

EGGXYT addresses a specific, high-value pain point that the egg industry has been under regulatory and public pressure to solve for over a decade — male chick culling — with a technology that intervenes at day 1, before incubation, which is technically more challenging and commercially more attractive than competing approaches that require candling at day 9 or later. As an Israeli company successfully funded through EU H2020 competitive calls, they bring external innovation into the European agri-food space without being beholden to any single European hatchery group or integrator. For potential partners in animal welfare compliance, hatchery automation, or egg industry supply chain, EGGXYT offers a validated, EU-funded technology with a clear commercial problem-solution fit.

Highlights from their portfolio

• eggXYt (SME-2)
  The largest grant (€2.33M) and longest project (2019–2022) represents the full commercial development phase of their core technology — the most significant single commitment in their portfolio.
• eggXYt (SME-1)
  The 2017 feasibility study (€50K) is notable as the proof-of-concept gate that unlocked the subsequent multi-million euro development grant, demonstrating a clean technology validation path.